Oncotarget

Vol 10, No 25

March 29, 2019

View Archive »

Order a Reprint

About The Cover

The cover for issue 25 of Oncotarget features Figure 5, "Cause-specific mortality by histological subtype (n=64,645)," by Gage, et al.

Table of Contents

Editorial

New mechanistic insights into modifiable risk factors that promote pancreatic cancer

New mechanistic insights into modifiable risk factors that promote pancreatic cancer

https://doi.org/10.18632/oncotarget.26813

Supriya Srinivasan, Austin R. Dosch,  and Nagaraj S. Nagathihalli
2417-2418
PDF  |  How to cite  |  Order a Reprint

Do tumor cells escape from natural killer cell cytotoxicity by mimicking dendritic cells?

Do tumor cells escape from natural killer cell cytotoxicity by mimicking dendritic cells?

https://doi.org/10.18632/oncotarget.26815

Hannah Wurzer, Antoun Al Absi, Céline Hoffmann,  and Clément Thomas
2419-2420
PDF  |  How to cite  |  Order a Reprint

BRCAness in prostate cancer

BRCAness in prostate cancer

https://doi.org/10.18632/oncotarget.26818

Natalia Bednarz-Knoll, Elke Eltze, Axel Semjonow,  and Burkhard Brandt
2421-2422
PDF  |  How to cite  |  Order a Reprint

Research Papers

Prediction of onset of remnant gastric cancer by promoter DNA methylation of CDO1/HOPX/Reprimo/E-cadherin

Prediction of onset of remnant gastric cancer by promoter DNA methylation of CDO1/HOPX/Reprimo/E-cadherin

https://doi.org/10.18632/oncotarget.26814

Keita Kojima, Naoko Minatani, Hideki Ushiku, Satoru Ishii, Toshimichi Tanaka, Keigo Yokoi, Nobuyuki Nishizawa, Yosuke Ooizumi, Kazuharu Igarashi, Kei Hosoda, Hiromitsu Moriya, Hiroaki Mieno, Masahiko Watanabe,  and Keishi Yamashita
2423-2434
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  How to cite  |  Order a Reprint

Development and characterization of a cancer cachexia model employing a rare human duodenal neuroendocrine carcinoma-originating cell line

Development and characterization of a cancer cachexia model employing a rare human duodenal neuroendocrine carcinoma-originating cell line

https://doi.org/10.18632/oncotarget.26764

Kazuyoshi Yanagihara, Takanori Kubo, Yuki Iino, Keichiro Mihara, Chie Morimoto, Toshio Seyama, Takeshi Kuwata, Atsushi Ochiai,  and Hiroshi Yokozaki
2435-2450
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  How to cite  |  Order a Reprint

177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

https://doi.org/10.18632/oncotarget.26789

Finn Edler von Eyben, Aviral Singh, Jingjing Zhang, Karin Nipsch, Danielle Meyrick, Nat Lenzo, Kalevi Kairemo, Timo Joensuu, Irene Virgolini, Cigdem Soydal, Harshad R. Kulkarni,  and Richard Paul Baum
2451-2461
Abstract  |  PDF  |  HTML  |  How to cite  |  Order a Reprint

Sarcomas in the United States: Recent trends and a call for improved staging

Sarcomas in the United States: Recent trends and a call for improved staging

https://doi.org/10.18632/oncotarget.26809

Michele M. Gage, Neeraja Nagarajan, Jessica M. Ruck, Joseph K. Canner, Salma Khan, Katherine Giuliano, Faiz Gani, Christopher Wolfgang, Fabian M. Johnston,  and Nita Ahuja
2462-2474
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  How to cite  |  Press Release  |  Order a Reprint

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers

https://doi.org/10.18632/oncotarget.26810

Tasnim Zaman, Ping Sun, Steven A. Narod, Leonardo Salmena,  and Joanne Kotsopoulos
2475-2483
Abstract  |  PDF  |  HTML  |  How to cite  |  Order a Reprint


Copyright © 2019 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC